ArticleGeriatrics & gerontology international2026
Association of Frailty and Its Trajectories With the Risk of Cardiovascular-Kidney-Metabolic Syndrome Progression: A Longitudinal Cohort Study.
Article in Geriatrics & gerontology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- When Cumulative Frailty Includes Future CVD Events: Time-Order Concerns in CKM Syndrome Research.Geriatrics & gerontology international · 2026Article
- Comment on: "Association of Frailty and Its Trajectories With the Risk of Cardiovascular-Kidney-Metabolic Syndrome Progression: A Longitudinal Cohort Study".Geriatrics & gerontology international · 2026Article
- Temporal Overlap Between Longitudinal Frailty Assessment and Cardiovascular Outcome Ascertainment.Geriatrics & gerontology international · 2026Article
- Letter to the Editor Regarding "Association of Frailty and Its Trajectories With the Risk of Cardiovascular-Kidney-Metabolic Syndrome Progression: A Longitudinal Cohort Study".Geriatrics & gerontology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsFrailty reflects a decline in physiological reserve and has been widely recognized as an important risk factor for cardiovascular disease (CVD). However, the relationships between frailty and the progression of the cardiovascular-kidney-metabolic (CKM) syndrome, as well as between dynamic frailty trajectories and CVD risk, have not been systematically investigated.
methodsA total of 5624 participants from the China Health and Retirement Longitudinal Study (CHARLS) were included. The association between baseline frailty and CVD risk was analyzed using the Cox proportional hazards model and the restricted cubic spline analyses. We used Group-based trajectory modeling (GBTM) to identify trajectories of frailty development during the follow-up periods from 2011 to 2018.
resultsHigher baseline frailty index (FI) was significantly associated with CVD risk in individuals with CKM syndrome stages 0-3; each 0.1 increase in FI was associated with a 33% higher risk of CVD after full adjustment (HR 1.33, 95% CI 1.26-1.40). Cumulative frailty burden, assessed using the cumulative FI (cumFI), showed a strong graded association with CVD risk. Three distinct frailty trajectories were identified. Compared with the low-level increasing trajectory, moderate-level and high-level increasing trajectories were associated with higher CVD risk (HR = 4.63, 95% CI: 3.50-6.14, HR = 9.33, 95% CI: 6.89-12.64). These associations were consistent across multiple sensitivity analyses.
conclusionsFrailty is associated with the risk of CKM syndrome progression. Beyond baseline assessment, cumFI and frailty trajectories provide prognostic information for cardiovascular risk. Dynamic assessment and early intervention targeting frailty may offer a strategy for preventing CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.